Results 41 to 50 of about 22,744 (213)

Chemokine Ligand 5 to Predict Optimal Cytoreduction in Ovarian Cancer

International Journal of General Medicine, 2020
Yudi Mulyana Hidayat,1 Munizar,1 Ali Budi Harsono,1 Gatot Nyarumenteng Adhipurnawan Winarno,1 Hasanuddin,2 Siti Salima1 1Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia; 2Department of Obstetrics ...
Hidayat YM, Munizar, Harsono AB, Winarno GNA, Hasanuddin, Salima S   +5 more
doaj  

The Yin and Yang of Cytoreductive SBRT in Oligometastases and Beyond

Frontiers in Oncology, 2019
Background: Oligometastatic disease has emerged as a possibly distinct metastatic phenotype in numerous cancer histologies. With the advancement in treatment modalities including stereotactic body radiation therapy (SBRT), certain patients may derive ...
Benjamin E. Onderdonk, Steven J. Chmura
doaj   +1 more source

Ovarian cancer: Is an expert surgical oncologist mandatory? [PDF]

Journal of Clinical and Investigative Surgery, 2019
Ovarian cancer has the worst prognosis of all gynecologic malignancies. The standard treatment of patients with ovarian cancer is a multidisciplinary assignment involving aggressive surgery with or without chemotherapy.
Montassar Ghaleb, Hanen Bouaziz, Sarah Sghaier, Maher Slimane, Hatem Bouzaiene, Jamel Ben Hassouna, Tarek Ben Dhiab, Monia Hechiche, Riadh Chargui, Khaled Rahal   +9 more
doaj   +1 more source

Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer [PDF]

, 2011
BACKGROUND: Ovarian cancer is the sixth most common cancer among women and the leading cause of death in women with gynaecological malignancies. Opinions differ regarding the role of ultra-radical (extensive) cytoreductive surgery in ovarian cancer ...
Ang, C, Bryant, A, Chan, KKL, Dickinson, HO, Naik, R   +4 more
core   +1 more source

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]

, 2018
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo, Barbui, Tiziano, Beggiato, Eloise, Bellini, Marta, Bertozzi, Irene, Betti, Silvia, Bonifacio, Massimiliano, Cacciola, Emma, Cacciola, Rossella, Carli, Giuseppe, Carobbio, Alessandra, Cattaneo, Daniele, Cazzola, Mario, Censori, Bruno, Cervantes, Francisco, Cortelezzi, Agostino, De Stefano, Valerio, Di Lazzaro, Vincenzo, Elli, Elena Maria, Ellis, Martin H., Finazzi, Guido, Finazzi, Maria Chiara, Gaidano, Gianluca, Gomez, Montse, Griesshammer, Martin, Guglielmelli, Paola, Hernandez-Boluda, Juan-Carlos, Iurlo, Alessandra, Loscocco, Giuseppe Gaetano, Lunghi, Francesca, Miroslava, Palova, Musolino, Caterina, Palandri, Francesca, Randi, Maria Luigia, Rapezzi, Davide, Rossi, Elena, Rumi, Elisa, Sadjadian, Parvis, Scaffidi, Luigi, Tieghi, Alessia, Vannucchi, Alessandro M., Vianelli, Nicola   +41 more
core   +5 more sources

Peritoneal carcinosis of ovarian origin [PDF]

, 2010
Epithelial ovarian cancer (EOC) is the second most common genital malignancy in women and is the most lethal gynecological malignancy, with an estimated five-year survival rate of 39%.
Fagotti, A, Fanfani, F, Gallotta, V, Naldini, A, ROMANO, Federico, Rossitto, C, Scambia, G., Vigliotta, M   +7 more
core   +2 more sources

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Socioeconomic impact on quality of care in pelvic gynecological cancers

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Introduction Several European studies have shown health‐related social inequalities in pelvic gynecological cancers, with a social gradient in incidence and mortality, partly explained by more advanced stages at diagnosis in low socioeconomic populations.
Lea Mauny, Camille Mimoun, Morgane Michel, Bérengère Tate, Martin Koskas, Blandine Colmont, Abida Haneefa, Corine Alberti, Karine Chevreul, Cyrille Huchon   +9 more
wiley   +1 more source

Search for New Participants in the Pathogenesis of High-Grade Serous Ovarian Cancer with the Potential to Be Used as Diagnostic Molecules

Life, 2022
Recent studies have attempted to develop molecular signatures of epithelial ovarian cancer (EOC) based on the quantitation of protein-coding and non-coding RNAs to predict disease prognosis.
Angelika V. Timofeeva, Aleksandra V. Asaturova, Maya V. Sannikova, Grigory N. Khabas, Vitaliy V. Chagovets, Ivan S. Fedorov, Vladimir E. Frankevich, Gennady T. Sukhikh   +7 more
doaj   +1 more source

Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity. [PDF]

, 2012
Although chemotherapy is used to treat most advanced solid tumors, recurrent disease is still the major cause of cancer-related mortality. Cancer stem cells (CSCs) have been the focus of intense research in recent years because they provide a possible ...
de la Cruz, Cecile, Eastham-Anderson, Jeffrey, Hegde, Ganapati V, Jackson, Erica L, Sweet-Cordero, E Alejandro, Zheng, Yanyan   +5 more
core   +2 more sources